3 x Phase 3 und unter Cashbestand !
Seite 5 von 7 Neuester Beitrag: 25.04.21 02:51 | ||||
| Eröffnet am: | 05.08.10 09:13 | von: Biotechmaste. | Anzahl Beiträge: | 161 |
| Neuester Beitrag: | 25.04.21 02:51 | von: Yvonnephxga | Leser gesamt: | 44.150 |
| Forum: | Hot-Stocks | Leser heute: | 20 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | 4 | | 6 | 7 > | ||||
Dieser zock ging gründlich in die hose ....
MFG
Chali
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Veloxis Pharmaceuticals |
Klang alles wirklich sehr vielversprechend und nun kommt da irgendwie garnix mehr.
Ist alles sehr dubios.
Warten wir mal den 1.März ab. Da soll es ja den Geschäftsbericht 2010 geben. Vielleicht gibt es ja dann auch noch ein paar Infos dazu.
Wäre ja mal was.
Gruß
Cyberhonk
Optionen
| Boardmail an "Cyberhonk" |
Wertpapier: Veloxis Pharmaceuticals |
BIO CEO & Investor Conference
LifeCycle Pharma A/S (OMX: LCP) today announced that William J. Polvino, M.D., president and chief executive officer, will present at the 13th Annual BIO CEO & Investor Conference at 10:30 a.m. EST, February 14, 2011, at the Waldorf-Astoria Hotel in New York City. Dr. Polvino will provide an overview of the company and its lead Phase 3 candidate to prevent organ transplant rejection, LCP-Tacro.
For U.S. investor and media contacts:
§
John Weinberg, M.D., Senior VP, Commercial Development and Strategic Planning
§
LifeCycle Pharma A/S
§
(732) 321-3208
§
jdw@lcpha r ma.com
§
About LifeCycle Pharma A/S (LCP)
Based in Horsholm, Denmark, with an office in New Jersey, LCP is a specialty pharmaceutical company. Clinical development is the core of LCP's efforts to develop a product portfolio which includes the Company's lead product candidate, LCP-Tacro™, for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability - at low-scale up costs - not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a lipid lowering product, Fenoglide®, currently on the U.S. market and a diversified near and medium term pipeline with three clinical stage product candidates and a number of projects in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: LCP.
Quelle: http://pr-usa.net/...ontent&task=view&id=623497&Itemid=33
Optionen
| Boardmail an "Cyberhonk" |
Wertpapier: Veloxis Pharmaceuticals |
in der usa sind es fast 40 mio. menschen, aber wieviele sind es in indien?
die krankheit ist aber nicht nur wegen fleisch, sondern auch eine veranlagung sache,
nüsse bringen die werte genauso in die höhe.
William J. Polvino M.D president and CEO of Veloxis Pharmaceuticals A/S, will present at the 14th Annual BIO CEO & Investor Conference at 3 p.m. EST, Tuesday, Feb. 14, at The Waldorf-Astoria in New York. Dr. Polvino will present an overview of the company and discuss top-line Phase 3 results of LCP-Tacro', Veloxis' candidate to prevent organ transplant rejection.
http://www.finanznachrichten.de/...io-ceo-investor-conference-252.htm
gibt es meinungen darüber
22-05-2014 COMMENTS (0)EnvarsusEuropeImmunologicalsPharmaceuticalRegulationVeloxis Pharmaceuticals
0 0 0 0
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has today adopted a positive opinion recommending marketing authorization for Denmark-based Veloxis Pharmaceuticals’ (OMX: VELO) Envarsus((once-daily tacrolimus; formerly LCP-Tacro)) for the prevention of organ rejection in adult transplant patients in the European Union.
The positive opinion is for both kidney and liver transplant recipients and includes both the de novo transplant and "switch" settings, as well as for treatment of rejection episodes resistant to treatment with other immunosuppressive products in adult patients. The CHMP's decision will be referred to the European Commission and if approved by the EC, Veloxis will receive marketing authorization for Envarsus in all member states of the EU. The EC is expected to render a final decision within three months of the opinion.
Key points
The positive opinion of the CHMP is based on review of the favorable results of the Envarsus Phase III 3001 study in stable kidney transplant patients and 3002 study in de novo kidney transplant recipients as well as data from an extensive Phase I and II clinical program, which included both kidney and liver transplant patients.
Studies 3001 and 3002 demonstrated that Envarsus dosed once-daily was not inferior to the current leading transplant drug, Prograf (tacrolimus), dosed twice-daily. The Phase I pharmacokinetic and Phase II efficacy data that was submitted in the MAA enabled extrapolation into the broader populations of both kidney and liver transplant recipients.
The US Food and Drug Administration has accepted for review Veloxis' New Drug Application for Envarsus for the prevention of organ rejection in kidney transplant patients and has set an action date of October 30, 2014 to respond to the submission. Veloxis does not expect to receive the additional liver indication in the USA.
Envarsus has received Orphan Drug Designation by the US FDA for prophylaxis of organ rejection in patients receiving allogeneic kidney transplants.
William Polvino, chief executive of Veloxis, commented: "The positive CHMP opinion for both the kidney and liver transplant patient populations in the European Union reflects the potential promise of Envarsus for the two largest segments of solid organ transplant recipients. This is an important milestone for Veloxis as we move closer to bringing Envarsus to market in the European Union. Veloxis, and our European marketing partner, Chiesi Farmaceutici, look forward to making this important therapeutic option available to transplant recipients."
Veloxos Pharma, Envarsus, EMA, CHMP, Positive opinion, Organ rejection, Kidney, Liver transplant
LEFT
RIGHT
6 OF 10
READ ALL TODAY'S ISSUE IN FULL
Your Comments
Login to add a comment
There are no comments yet. Be the first and leave a response!